FBRX - CIK 0001419041
The table below shows Forte Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$50.88M | -$30.75M | -$28.71M | -$8.19M | -$16.68M | -$18.42M |
| Capital expenditure | $116.00K | $37.00K | $88.00K | - | - | - |
| Investing cash flow | $36.23M | -$35.99M | $47.00K | - | - | $3.58M |
| Dividends paid | - | - | - | - | - | - |
Forte Biosciences, Inc. reported operating cash flow of -$50.88M for fiscal year 2025. That is down 65.5% from -$30.75M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$29.54M (FY 2016) to -$50.88M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $69.36M | $51.86M | $24.68M | $7.24M | -$44.00K | $66.67M |